Abstract
The guidelines in the management of pemphigus have evolved over the years to enhance treatments outcomes and prognosis. Rituximab (RTX) is today the first-line therapy for moderate to severe pemphigus. Objective to assess the response of RTX and to compare its efficacy as 1st or 2nd line treatment. We conducted a single-center retro-prospective study in the dermatology department of Ibn Sina university hospital of Rabat (2007-2021). 43 patients were included, 17 in the “naive” group and 26 in the “non-naive” group, 81% with severe initial PDAI score.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
